Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6880531 | 1.00 | EPHX1 (0.39) | EPHX1TP53DPP4KDM4EGMNN | |
| SCHEMBL2396925 | 0.97 | — | — | |
| SCHEMBL16640291 | 0.74 | EPHX1 (0.39) | EPHX1TP53DPP4KDM4EGMNN | |
| SCHEMBL5646565 | 0.74 | EPHX1 (0.41) | EPHX1TP53DPP4KDM4EGMNN | |
| SCHEMBL2292764 | 0.74 | EPHX1 (0.39) | EPHX1TP53DPP4KDM4EGMNN | |
| SCHEMBL4040242 | 0.74 | EPHX1 (0.41) | EPHX1TP53DPP4KDM4EGMNN | |
| SCHEMBL7139260 | 0.73 | EPHX1 (0.34) | EPHX1TP53DPP4KDM4EGMNN | |
| SCHEMBL4624168 | 0.72 | NCF1 (0.37) | — | |
| SCHEMBL15045495 | 0.72 | — | — | |
| SCHEMBL4042923 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| CN-111225900-A | 3, 4-disubstituted 3-cyclobutene-1, 2-diones and their use | 阿勒根公司 | 2020-06-02 | — | — | CN | disclosed |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2019-02-14 | — | — | US | disclosed |
| US-9245290-B2 | Caspase inhibitors and uses thereof | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140011847-A1 | CASPASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-01-09 | — | — | US | disclosed |
| US-8518942-B2 | Caspase inhibitors and uses thereof | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110230527-A1 | CASPASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230527-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP6, CASP3, CASP2 | EPHX1 1297/4885TP53 1817/4885DPP4 114/4885 |
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | EPHX1 2831/4885TP53 4052/4885DPP4 455/4885 |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | IL17A, TSLP, SSB | EPHX1 2831/4885TP53 4052/4885DPP4 455/4885 |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | EPHX1 2831/4885TP53 4052/4885DPP4 455/4885 |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | EPHX1 2831/4885TP53 4052/4885DPP4 455/4885 |
| US-20140011847-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP6, CASP3, CASP2 | EPHX1 1297/4885TP53 1817/4885DPP4 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.